After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Gilead Sciences, Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Drug Manufacturers – General industry. The current market capitalization of Gilead Sciences, Inc. is $84.48B. A total of 7.71 million shares were traded on the day, compared to an average of 7.41M shares.
In the most recent transaction, GILEAD SCIENCES, INC. bought 485,250 shares of GILD for 0.76 per share on Apr 02 ’24. After the transaction, the 10% Owner now owns 7,345,473 company shares. In a previous transaction on Apr 01 ’24, Parsey Merdad sold 2,000 shares at 72.96 per share. GILD shares that Chief Medical Officer owns now total 96,304.
Among the insiders who sold shares, Parsey Merdad disposed of 8,230 shares on Feb 29 ’24 at a per-share price of $72.74. This resulted in the Chief Medical Officer holding 92,706 shares of GILD after the transaction. In another insider transaction, Parsey Merdad sold 2,000 shares at $73.18 per share on Feb 28 ’24. Company shares held by the Chief Medical Officer now total 100,936.
Dividend
The reasons why investors prefer dividend-paying companies are that dividends generate immediate cash flow and indicate that the company will perform well in the future. Gilead Sciences, Inc. pays an annual dividend of $3.02, resulting in a dividend yield of 4.46%, and it has a price to earnings (P/E) ratio of 15.04. GILD’s most recent ex-dividend date was 3/14/2024 when it declared a $0.77 quarterly dividend that was paid in cash on 3/28/2024. Previously, the company paid the dividend on 12/28/2023 with an ex-dividend date of 12/14/2023. The GILD stock dividend was $0.75 per share in cash.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, GILD has a high of $87.86 and a low of $67.62.
As of this writing, GILD has an earnings estimate of $SPDR Gold Trust per share for the current quarter. EPS was calculated based on a consensus of Barrick Gold Corporation estimates, with a high estimate of $GBLD per share and a lower estimate of $Gilead Sciences, Inc..
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. GILD’s latest balance sheet shows that the firm has $6.52B in Cash & Short Term Investments as of fiscal 2021. There were $26.70B in debt and $11.61B in liabilities at the time. Its Book Value Per Share was $18.33, while its Total Shareholder’s Equity was $21.06B.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for GILD is Buy with a score of 3.83.
